Renflexis and Infusion site extravasation - a phase IV clinical study of FDA data

Summary:

Infusion site extravasation is reported as a side effect among people who take Renflexis (infliximab-abda), especially for people who are male, 20-29 old, have been taking the drug for < 1 month also take Prednisone, and have Crohn's disease.

The phase IV clinical study analyzes which people have Infusion site extravasation when taking Renflexis. It is created by eHealthMe based on reports of 1,311 people who have side effects when taking Renflexis from the FDA, and is updated regularly.

What is Renflexis?

Renflexis has active ingredients of infliximab-abda. eHealthMe is studying from 1,316 Renflexis users. Check the latest studies of Renflexis.

What is Infusion site extravasation?

Infusion site extravasation (flow of (blood or lymph) from infusion site) is found to be associated with 649 drugs and 590 conditions by eHealthMe. Check the latest studies of Infusion site extravasation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

1,311 people reported to have side effects when taking Renflexis.
Among them, 23 people (1.75%) have Infusion site extravasation.

Could Renflexis cause Infusion site extravasation?

Among these 23 people:

How long have people been on Renflexis when they have Infusion site extravasation? *

What is the gender of people who have Infusion site extravasation when taking Renflexis? *

female: 41.18 %
male: 58.82 %

What is the age of people who have Infusion site extravasation when taking Renflexis? *

What are other drugs people take besides Renflexis? *

What are other side effects people have besides Infusion site extravasation? *

Infusion Site Swelling: 8 people, 34.78%
Feeling Cold: 7 people, 30.43%
Infusion Site Pain: 7 people, 30.43%
Poor Venous Access: 6 people, 26.09%
Rashes (redness): 5 people, 21.74%
Ill-Defined Disorder: 5 people, 21.74%
Cellulitis (infection under the skin): 4 people, 17.39%
Injection Site Pain: 4 people, 17.39%
Eye Swelling: 4 people, 17.39%
Ocular Hyperaemia (an abnormally large amount of blood in eye): 4 people, 17.39%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 11 people, 47.83%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 7 people, 30.43%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 8.70%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Renflexis and have Infusion site extravasation?

- Check whether Infusion site extravasation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Renflexis:

Renflexis (1,316 reports)

Browse all side effects of Renflexis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site extravasation:

Infusion site extravasation (649 drugs)

Browse all the conditions that are associated with Infusion site extravasation:

Infusion site extravasation (590 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab-abda (the active ingredients of Renflexis) and Renflexis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.